Review of: "[Research Note] Unveiling the Interplay of Klotho Protein, Chemotherapy-Induced Klotho Protein Deficiency, and the Pivotal Role of GLP-1 Agonists like Ozempic in Cancer Survivorship Patient Survival Rate after Chemotherapy Treatment"

Joaquim Barreto[1]

1 University of Campinas (Unicamp)

Potential competing interests: No potential competing interests to declare.

In this manuscript, Akl et al. presents a dedicated review of the potential effects of widely used chemotherapy treatment agents, principally alkylant agents, on kidney protein deficiency, particularly of Klotho. Authors additionally comment that, as glucose lowering peptide 1 agonists positively influence Klotho leves, this class could plausibly attenutate chemotherapy-induced Klotho deficiency, which could play a clinical role in preventing kidney outcomes and long-term, clinically relevant, disability. The manuscrip is overall adequate, well-written, and the topic is of relevance. It should, unless otherwise believed by the editors of this eminent journal, be considered for publication.